Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non–Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial

Nonparametric Estimation from Incomplete Observations

1958 • 37,219 citations

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

2002 • 4,805 citations

COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER

2002 • 3,803 citations

Optimal two-stage designs for phase II clinical trials

1989 • 3,494 citations

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

2003 • 2,871 citations

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

1995 • 2,804 citations

Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials

1996 • 2,541 citations

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

2004 • 2,376 citations

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1975 • 2,224 citations

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

1989 • 1,831 citations

Applied Biopharmaceutics and Pharmacokinetics.

1981 • 1,335 citations

Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial

2001 • 1,145 citations

Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group

2003 • 946 citations

Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer

2002 • 896 citations

A Confidence Interval for the Median Survival Time

1982 • 831 citations

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1992 • 619 citations

Oxaliplatin: A review of preclinical and clinical studies

1998 • 611 citations

Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia

2002 • 306 citations

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

2002 • 302 citations

Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.

1998 • 302 citations

Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B₁₂ as Front-Line Therapy in Malignant Pleural Mesothelioma

2003 • 260 citations

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

2002 • 245 citations

Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scale

1994 • 236 citations

Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study

1998 • 230 citations

Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study

1999 • 217 citations

Pemetrexed Disodium: A Novel Antifolate Clinically Active Against Multiple Solid Tumors

2001 • 205 citations

Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial

2003 • 163 citations

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™ and cisplatin: A multicenter phase II trial

2000 • 153 citations

Synthesis of pyrazolo 3,4-pyrimidine analogues of the potent agent N-4-2-2-amino-4 3-oxo-7-pyrrolo 2,3-pyrimidin-5-yl ethylbenzoyl-L-glutamic acid (LY231514)

1992 • 150 citations

Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma

2002 • 149 citations

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma

2001 • 149 citations

Clinical oncology : a multidisciplinary approach for physicians and students

1993 • 123 citations

Phase II trial of pemetrexed disodium (ALIMTA®, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer

2002 • 120 citations

Pemetrexed (Alimta^®): a novel multitargeted antifolate agent

2003 • 92 citations

Molecular, biochemical, and cellular pharmacology of pemetrexed

2002 • 87 citations

Molecular, biochemical, and cellular pharmacology of pemetrexed

2002 • 76 citations

Phase II Trial of Paclitaxel Plus Gemcitabine in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

2001 • 51 citations

Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study

2002 • 38 citations

Synthesis of Thieno[2,3-d]pyrimidine Analogues of the Potent Antitumor Agent N-{4-[2-(2-Amino-4(3H)-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic Acid (LY231514)

1996 • 30 citations

Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors

2004 • 29 citations

Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC

2004 • 27 citations

P-522 A phase II trial of Alimta plus carboplatin (AC) in patients (pts) with advanced non-small-cell lung cancer (NSCLC)

2003 • 7 citations